Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Blog

Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 MillionPhoto, wide shot, wide-angle lens, soft focus,  Pharmaceutical company, sunset photo at golden hour, photo by Peter Lik: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-TIgKJfhK8q44RPNTTsL9npu7.png?st=2023-05-08T05%3A58%3A04Z&se=2023-05-08T07%3A58%3A04Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-05-08T02%3A36%3A56Z&ske=2023-05-09T02%3A36%3A56Z&sks=b&skv=2021-08-06&sig=BDDjRcmCPf%2BH//HSxRGZYByMqOKev8lx0/Dhvka/lXk%3D
Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million

On February 17, 2026, Perceptive Advisors disclosed a significant buy of 431,432 shares of Praxis Precision Medicines (NASDAQ:PRAX), with an estimated transaction value of $80.34 million based on

Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two PositionPhoto, wide shot, wide-angle lens, soft focus,  Pharmaceutical company, sunset photo at golden hour, photo by Peter Lik: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-TIgKJfhK8q44RPNTTsL9npu7.png?st=2023-05-08T05%3A58%3A04Z&se=2023-05-08T07%3A58%3A04Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-05-08T02%3A36%3A56Z&ske=2023-05-09T02%3A36%3A56Z&sks=b&skv=2021-08-06&sig=BDDjRcmCPf%2BH//HSxRGZYByMqOKev8lx0/Dhvka/lXk%3D
Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position

On February 17, 2026, Perceptive Advisors reported a buy of Celcuity (NASDAQ:CELC), adding 203,881 shares in the fourth quarter, with an estimated transaction value of $16.76 million based on

2 Financial Stocks Poised for a Comeback in 2026Photo, wide shot, wide-angle lens,  Janitorial service, Midday, harsh overhead sunlight, directional sunlightt, photo by Ansel Adams: https://img.midjourneyapi.xyz/temp/4d4e885c-79e9-4b8f-bd91-e9721cd7c2e9.png
2 Financial Stocks Poised for a Comeback in 2026

Two of the most consistent, reliable, and best financial stocks over the past decades -- Visa (NYSE: V) and Moody's (NYSE: MCO) -- have struggled in recent months.

Visa, the leading payment

Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction
Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction

On February 17, 2026, Perceptive Advisors disclosed a buy of 978,662 shares of Apogee Therapeutics (NASDAQ:APGE), with an estimated transaction value of $61.64 million based on quarterly average

My 5 Favorite Dividend Stocks to Buy Right Now
My 5 Favorite Dividend Stocks to Buy Right Now

Does your portfolio need some new income investments? Maybe you're looking for a little more certainty -- and defensiveness -- now that a few too many risky growth stocks are overbought as well as

Are You Really Ready to Start Collecting Social Security? 3 Signs It Might Be the Perfect Time
Are You Really Ready to Start Collecting Social Security? 3 Signs It Might Be the Perfect Time

As you approach retirement, there are a few decisions you should consider to make sure you're as financially prepared as possible. This includes when you want to start taking withdrawals from your

$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges
$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges

Perceptive Advisors disclosed a sale of 1,002,282 Arcellx (NASDAQ:ACLX) shares in a February 17, 2026, SEC filing, with the estimated transaction value at $79.96 million based on quarterly average

Leveraged ETFs Are Among the Market's Most Aggressive Investment Tools. But Should You Avoid Them Altogether?
Leveraged ETFs Are Among the Market's Most Aggressive Investment Tools. But Should You Avoid Them Altogether?

There are always investors who want to get rich as quickly as possible. That's why Wall Street has happily created exchange-traded funds (ETFs) that deliver double or even triple the market's

Arohi Asset Exits a Big Software Bet by Selling 1.7M DoubleVerify (DV) Shares Worth $20.6 MillionPhoto, wide shot, wide-angle lens,  Artificial intelligence developer, sunset photo at golden hour, photo by Ansel Adams: https://img.midjourneyapi.xyz/temp/ee32e77c-b7d6-424b-91ea-4023f2292688.png
Arohi Asset Exits a Big Software Bet by Selling 1.7M DoubleVerify (DV) Shares Worth $20.6 Million

According to an SEC filing dated Feb. 18, 2026, Arohi Asset Management PTE Ltd. sold all 1,717,770 shares of DoubleVerify (NYSE: DV) during the fourth quarter. The estimated transaction value was

Could Buying XRP Today Set You Up for Life?
Could Buying XRP Today Set You Up for Life?

The formerly high-flying cryptocurrency XRP (CRYPTO: XRP) is down a head-spinning 60% over the past six months. That might not sound like the type of investment that could set you up for life.

Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 MillionPhoto, wide shot, wide-angle lens,  Mental health care service, Midday, harsh overhead sunlight, directional sunlightt, photo by Art Wolfe: https://img.midjourneyapi.xyz/temp/7ce3b930-5e2a-4215-b686-0ad0eb0b922a.png
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million

On February 17, 2026, Redmile Group disclosed a buy of 4,415,514 Nurix Therapeutics (NASDAQ:NRIX) shares, an estimated $63.43 million trade based on quarterly average pricing.

According to a

Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120%Photo, wide shot, wide-angle lens,  Medical device manufacturer, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Michael Light: https://img.theapi.app/temp/3a7f6312-1eee-4702-9005-93cc1e62f970.png
Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120%

On February 17, 2026, Redmile Group disclosed a buy of 695,000 shares of Immunome (NASDAQ:IMNM), an estimated $12.20 million trade based on quarterly average pricing.

According to a February 17,

Johnson & Johnson: This Dividend King Could Anchor a Millionaire Retirement Portfolio
Johnson & Johnson: This Dividend King Could Anchor a Millionaire Retirement Portfolio

Whether you plan on retiring a millionaire or already are one, your investing strategy is likely shifting over time. You spend your working years looking for upside in the name of growing your nest

Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year
Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year

Redmile Group disclosed a significant reduction in its Zymeworks (NASDAQ:ZYME) position in a February 17, 2026, SEC filing, selling an estimated $70.10 million in shares based on quarterly average

Vertiv Stock: Buy, Sell, or Hold?Photo, wide shot, wide-angle lens,  Cloud computing provider, sunset photo at golden hour, photo by Thomas Heaton: https://img.theapi.app/temp/8d7b6619-8b3b-4e9e-b659-68643d72528e.png
Vertiv Stock: Buy, Sell, or Hold?

Vertiv (NYSE: VRT) stock is a popular pick-and-shovel play on the increased build-out efforts related to artificial intelligence (AI) data centers. The company provides key cooling and power

Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025Photo, wide shot, wide-angle lens,  Biotech company, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Sebastião Salgado: https://img.theapi.app/temp/80e18bfd-1ff8-4487-af62-1cdb7de1ceb6.png
Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025

Redmile Group reported a purchase of 16,317 shares of Krystal Biotech (NASDAQ:KRYS) in its February 17, 2026, SEC filing, with the estimated transaction value at $3.43 million based on quarterly

Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26%Photo, wide shot, wide-angle lens,  Gold mine, Midday, harsh overhead sunlight, directional sunlightt, photo by Thomas Heaton: https://img.midjourneyapi.xyz/temp/94faf2bd-99c1-4ea6-b55d-fdcab23c3865.png
Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26%

Redmile Group disclosed a buy of 1,316,390 shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) in a February 17, 2026, SEC filing, with the estimated transaction value at $49.37 million based

Intuitive Surgical: This Robotic-Surgery Leader Could Keep Compounding for Another Decade
Intuitive Surgical: This Robotic-Surgery Leader Could Keep Compounding for Another Decade

Intuitive Surgical (NASDAQ: ISRG) has faced challenges over the past year. President Donald Trump's aggressive tariffs are impacting its financial results, and it's now facing more competition than

Dean Capital Bets Big on Energy Delivery With a 28,000 Share Investment in Chesapeake Utilities (CPK) Worth $3.5 MillionPhoto, wide shot, wide-angle lens,  Coal company, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by David Maisel: https://img.midjourneyapi.xyz/temp/2a011bdc-adca-4de9-8457-d868b31178cf.png
Dean Capital Bets Big on Energy Delivery With a 28,000 Share Investment in Chesapeake Utilities (CPK) Worth $3.5 Million

According to a new 13F filing with the Securities and Exchange Commission dated Feb. 20, 2026, Dean Capital Management disclosed a new position in Chesapeake Utilities Corporation (NYSE:CPK)

Why Cleveland's Culture Scene Makes It a Retirement Pick That Doesn't Feel "Sleepy"
Why Cleveland's Culture Scene Makes It a Retirement Pick That Doesn't Feel "Sleepy"

Founded in 1796, who ever dreamed that Cleveland, Ohio would become a hotspot for retirees who just want to have fun? There's nothing sleepy about this city on Lake Erie. In fact, retirees have to

Billionaire Stanley Druckenmiller Still Isn't Buying Nvidia. But He Recently Picked Up Shares of This AI Stock That's Among the Cheapest of the Magnificent Seven.Photo, wide shot, wide-angle lens,  Cloud computing provider, Midday, harsh overhead sunlight, directional sunlightt, photo by Thomas Heaton: https://img.midjourneyapi.xyz/temp/893880f6-c6d9-4518-b1a0-f0be05207ac4.png
Billionaire Stanley Druckenmiller Still Isn't Buying Nvidia. But He Recently Picked Up Shares of This AI Stock That's Among the Cheapest of the Magnificent Seven.

Stanley Druckenmiller, who oversees $4.4 billion at the Duquesne Family Office, owned Nvidia (NASDAQ: NVDA) stock, but sold all of his shares in 2024. At the time, he considered the AI giant richly

Alphabet Has a Plan for Worldwide AI DominancePhoto, wide shot, wide-angle lens,  Computer hardware manufacturer, sunset photo at golden hour, photo by Thomas Heaton: https://img.midjourneyapi.xyz/temp/a130cb51-4ded-41be-b600-b83e2078ad65.png
Alphabet Has a Plan for Worldwide AI Dominance

Alphabet (NASDAQ: GOOGL) (NASDAQ: GOOG) was slow out of the gate when it comes to artificial intelligence. Over the past year, though, the tech giant has roared back, staking its claim to be a

This Fund Sold its Entire Stake in SSR Mining Stock After a 200% Rally. Should You Too?Photo, wide shot, wide-angle lens,  Gold mine, Midday, harsh overhead sunlight, directional sunlightt, photo by Thomas Heaton: https://img.midjourneyapi.xyz/temp/94faf2bd-99c1-4ea6-b55d-fdcab23c3865.png
This Fund Sold its Entire Stake in SSR Mining Stock After a 200% Rally. Should You Too?

According to a Feb. 17, 2026, SEC filing, Condire Management, LP, fully exited its position in SSR Mining (NASDAQ:SSRM), selling 3,353,891 shares in a trade estimated at $81.90 million based on

Banking Crisis 2.0? The "Contagion" ETF That Gains 3% for Every 1% Banks DropPhoto, wide shot, wide-angle lens,  Private equity firm, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Edward Burtynsky: https://img.theapi.app/temp/2b695cca-48cb-4195-802a-e3385fb90ec0.png
Banking Crisis 2.0? The "Contagion" ETF That Gains 3% for Every 1% Banks Drop

Lost in the commotion of the Global Financial Crisis was the fact that, back then, exchange-traded funds (ETFs) were young. They still are in financial market terms, but in 2008, the State Street

This 5% Dividend Stock Looks Safer Than You Think
This 5% Dividend Stock Looks Safer Than You Think

Realty Income (NYSE: O) just expanded into Mexico and secured a $1.5 billion joint venture while maintaining a 5% monthly dividend. With 98.7% occupancy and long-term leases, this REIT is built for